TY  -  
T1  - Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer 
SN  -  /  
UR  - http://hdl.handle.net/10138/243771 
T3  -  
A1  - Bruun, Jarle; Sveen, Anita; Barros, Rita; Eide, Peter W.; Eilertsen, Ina; Kolberg, Matthias; Pellinen, Teijo; David, Leonor; Svindland, Aud; Kallioniemi, Olli; Guren, Marianne G.; Nesbakken, Arild; Almeida, Raquel; Lothe, Ragnhild A. 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colorectal cancer (CRC) according to disease stage and chemotherapy sensitivity in preclinical models. CDX2 expression was evaluated in 1045 stage I-IV primary CRCs by gene expression (n = 403) or immunohistochemistry (n = 642) and in relation to 5-year relapse-free survival (RFS), overall survival (OS), and chemotherapy. Pharmacogenomic associations between CDX2 expression and 69 chemotherapeutics were... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - CDX2; colorectal cancer; drug sensitivity; pharmacogenomics; predictive biomarker; prognostic biomarker; COLON-CANCER; MOLECULAR SUBTYPES; CELL-LINES; MICROSATELLITE INSTABILITY; MULTIDRUG-RESISTANCE; MISMATCH REPAIR; GASTRIC-CANCER; STAGE-II; EXPRESSION; MARKER; 3122 Cancers 
N1  -   
PP  -  
ER  -